Cytek Biosciences Stock (NASDAQ:CTKB)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.32

52W Range

$4.66 - $9.87

50D Avg

$6.03

200D Avg

$5.92

Market Cap

$834.70M

Avg Vol (3M)

$673.71K

Beta

1.32

Div Yield

-

CTKB Company Profile


Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

645

IPO Date

Jul 23, 2021

Website

CTKB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service$36.49M$15.44M$8.43M
Product$156.72M$148.60M$119.52M

Fiscal year ends in Dec 23 | Currency in USD

CTKB Financial Summary


Dec 23Dec 22Dec 21
Revenue$193.01M$164.04M$127.95M
Operating Income$-26.34M$-1.83M$6.45M
Net Income$-12.15M$2.58M$4.42M
EBITDA$-17.11M$3.83M$7.69M
Basic EPS$-0.09$0.02$0.05
Diluted EPS$-0.09$0.02$0.05

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 05, 24 | 8:26 PM
Q2 24Aug 11, 24 | 4:25 AM
Q1 24May 08, 24 | 12:00 AM

Peer Comparison


TickerCompany
APYXApyx Medical Corporation
OFIXOrthofix Medical Inc.
LUNGPulmonx Corporation
NPCENeuroPace, Inc.
SRDXSurmodics, Inc.
LIVNLivaNova PLC
KIDSOrthoPediatrics Corp.
SGHTSight Sciences, Inc.
SSKNSTRATA Skin Sciences, Inc.
AXGNAxoGen, Inc.
INGNInogen, Inc.
RXSTRxSight, Inc.